Potential of non-antiarrhythmic drugs to provide an innovative upstream approach to the pharmacological prevention of sudden cardiac death

被引：18

作者：

Boriani, Giuseppe ^{[1
]}

Valzania, Cinzia ^{[1
]}

Diemberger, Igor ^{[1
]}

Biffi, Mauro ^{[1
]}

Martignani, Cristian ^{[1
]}

Bertini, Matteo ^{[1
]}

Ziacchi, Matteo ^{[1
]}

Domenichini, Giulia ^{[1
]}

机构：

[1] Univ Bologna, Inst Cardiol, Policlin S Orsola Malpighi, I-40138 Bologna, Italy

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2007年 / 16卷 / 05期

关键词：

antiarrhythmic drugs; cardioverter defibrillator; sudden cardiac death;

D O I：

10.1517/13543784.16.5.605

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Sudden cardiac death (SCD) is the most common cause of death and often occurs in low-risk patients. Present prevention strategies, mainly confined to high-risk subjects (proposed implantable cardioverter defibrillators recipients), have a limited effect on SCD burden in the general population. A relatively unexplored strategy for extending SCD prevention could imply targeting the early (upstream) processes of the complex cascade leading to SCD by non-antiarrhythmic drugs (i.e., beta-blockers, aldosterone antagonists, angiotensin-converting enzyme inhibitors, angiotensin receptor-blocker agents, statins and omega-3 fatty acids). In this innovative pharmacological perspective, agents with upstream effects may also be used in high-risk patients in association with a strictly downstream intervention, such as the implantable cardioverter defibrillator, in an attempt to obtain an additive/synergetic effect.

引用

页码：605 / 623

页数：19